William Busse

List of Publications by Citations

233 papers	28,036 citations	78 h-index	165 g-index
261 ext. papers	32,611 ext. citations	8.5 avg, IF	7 L-index

#	Paper	IF	Citations
233	Asthma. *New England Journal of Medicine*, **2001**, 344, 350-62	59.2	1541
232	Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 315-23	10.2	1427
231	An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 180, 59-99	10.2	1304
230	Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 170, 836-44	10.2	1250
229	Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. *Journal of Allergy and Clinical Immunology*, **2001**, 108, 184-90	11.5	970
228	Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. *New England Journal of Medicine*, **2018**, 378, 2486-2496	59.2	763
227	Benralizumab, an anti-interleukin-5 receptor monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet, The*, **2016**, 388, 2128-2141	40	738
226	Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. *Journal of Allergy and Clinical Immunology*, **2007**, 119, 405-13	11.5	709
225	Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. *New England Journal of Medicine*, **2011**, 364, 1005-15	59.2	647
224	Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 804-11	10.2	609
223	A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 176, 1062-71	10.2	567
222	Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. *Lancet, The*, **2003**, 361, 1071-6	40	566
221	Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 170, 583-93	10.2	517
220	Role of viral respiratory infections in asthma and asthma exacerbations. *Lancet, The*, **2010**, 376, 826-34	40	495
219	Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 1294-302	10.2	422
218	Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. *Journal of Allergy and Clinical Immunology*, **2014**, 133, 1557-63.e5	11.5	377
217	Benralizumab, an anti-interleukin 5 receptor monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. *Lancet Respiratory Medicine,the*, **2014**, 2, 879-890	35.1	367

216	Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. *Annals of Internal Medicine*, **2011**, 154, 573-82	8	355
215	Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. *Journal of Allergy and Clinical Immunology*, **2015**, 136, 1476-1485	11.5	349
214	Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. *Lancet, The*, **2008**, 372, 1065-72	40	341
213	Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. *Journal of Allergy and Clinical Immunology*, **2013**, 132, 1086-1096.e5	11.5	320
212	Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti-IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 1294-1302	10.2	294
211	Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. *Journal of Allergy and Clinical Immunology*, **1997**, 100, 110-21	11.5	287
210	Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. *Journal of Allergy and Clinical Immunology*, **2020**, 146, 203-206.e3	11.5	285
209	Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. *Journal of Allergy and Clinical Immunology*, **2006**, 117, 134-40	11.5	277
208	Severe exacerbations and decline in lung function in asthma. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 179, 19-24	10.2	275
207	Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. *The American Review of Respiratory Disease*, **1991**, 144, 1274-81		265
206	Effects of early-life exposure to allergens and bacteria on recurrent wheeze and atopy in urban children. *Journal of Allergy and Clinical Immunology*, **2014**, 134, 593-601.e12	11.5	263
205	A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 788-96	10.2	254
204	The role of viral infections in the natural history of asthma. *Journal of Allergy and Clinical Immunology*, **2000**, 106, 201-12	11.5	251
203	School examinations enhance airway inflammation to antigen challenge. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 1062-7	10.2	229
202	Asthma: clinical expression and molecular mechanisms. *Journal of Allergy and Clinical Immunology*, **2010**, 125, S95-102	11.5	226
201	Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. *Journal of Allergy and Clinical Immunology*, **2010**, 125, 1237-1244.e2	11.5	222
200	Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. *Journal of Applied Physiology*, **2008**, 104, 394-403	3.7	218
199	Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 1033-41	10.2	215

198	Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 185, 356-62	10.2	198
197	Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. *Journal of Allergy and Clinical Immunology*, **2014**, 133, 1280-8	11.5	193
196	Severe asthma: lessons from the Severe Asthma Research Program. *Journal of Allergy and Clinical Immunology*, **2007**, 119, 14-21; quiz 22-3	11.5	183
195	Ragweed immunotherapy in adult asthma. *New England Journal of Medicine*, **1996**, 334, 501-6	59.2	182
194	Quantitative and qualitative analysis of rhinovirus infection in bronchial tissues. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 171, 645-51	10.2	182
193	Neural circuitry underlying the interaction between emotion and asthma symptom exacerbation. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 13319-24	11.5	165
192	DNA methylation and childhood asthma in the inner city. *Journal of Allergy and Clinical Immunology*, **2015**, 136, 69-80	11.5	157
191	Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. *Journal of Allergy and Clinical Immunology*, **1998**, 101, 457-63	11.5	157
190	Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. *Journal of Allergy and Clinical Immunology*, **2010**, 125, 383-9	11.5	154
189	Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. *Journal of Immunology*, **2002**, 169, 6452-8	5.3	154
188	Asthma Exacerbations: Pathogenesis, Prevention, and Treatment. *Journal of Allergy and Clinical Immunology: in Practice*, **2017**, 5, 918-927	5.4	146
187	Omalizumab in asthma: an update on recent developments. *Journal of Allergy and Clinical Immunology: in Practice*, **2014**, 2, 525-36.e1	5.4	145
186	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. *Lancet Respiratory Medicine,the*, **2019**, 7, 46-59	35.1	138
185	Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 985-992	10.2	135
184	Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. *Chest*, **2005**, 127, 1312-26	5.3	131
183	Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. *Journal of Allergy and Clinical Immunology*, **2019**, 143, 190-200.e20	11.5	127
182	Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 1002-8	10.2	122
181	A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. *Journal of Allergy and Clinical Immunology*, **2017**, 140, 162-169.e2	11.5	120

180	The relationship of airway hyperresponsiveness and airway inflammation: Airway hyperresponsiveness in asthma: its measurement and clinical significance. *Chest*, **2010**, 138, 4S-10S	5.3	116
179	Age-related changes in eosinophil function in human subjects. *Chest*, **2008**, 133, 412-9	5.3	116
178	High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. *Journal of Allergy and Clinical Immunology*, **2013**, 132, 485-6.e11	11.5	114
177	Omalizumab and the risk of malignancy: results from a pooled analysis. *Journal of Allergy and Clinical Immunology*, **2012**, 129, 983-9.e6	11.5	113
176	Seasonal risk factors for asthma exacerbations among inner-city children. *Journal of Allergy and Clinical Immunology*, **2015**, 135, 1465-73.e5	11.5	111
175	Type 2 immunity in the skin and lungs. *Allergy: European Journal of Allergy and Clinical Immunology*, **2020**, 75, 1582-1605	9.3	111
174	The effect of an experimental rhinovirus 16 infection on bronchial lavage neutrophils. *Journal of Allergy and Clinical Immunology*, **2000**, 105, 1169-77	11.5	105
173	The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. *Journal of Allergy and Clinical Immunology*, **2008**, 121, 1167-74	11.5	104
172	Relationship of viral infections to wheezing illnesses and asthma. *Nature Reviews Immunology*, **2002**, 2, 132-8	36.5	102
171	Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. *Lancet, The*, **2017**, 389, 157-166	40	100
170	Rhinovirus-induced PBMC responses and outcome of experimental infection in allergic subjects. *Journal of Allergy and Clinical Immunology*, **2000**, 105, 692-8	11.5	100
169	The presence of rhinovirus in lower airways of patients with bronchial asthma. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 177, 1082-9	10.2	98
168	Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study. *Journal of Allergy and Clinical Immunology: in Practice*, **2019**, 7, 156-164.e1	5.4	97
167	Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. *Journal of Allergy and Clinical Immunology*, **2008**, 121, 30-37.e6	11.5	94
166	Rhinovirus-induced interferon-gamma and airway responsiveness in asthma. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 168, 1091-4	10.2	94
165	Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. *Journal of Allergy and Clinical Immunology*, **2017**, 139, 1431-1444	11.5	93
164	Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. *Journal of Allergy and Clinical Immunology*, **2018**, 141, 1735-1743.e9	11.5	93
163	The nasal methylome and childhood atopic asthma. *Journal of Allergy and Clinical Immunology*, **2017**, 139, 1478-1488	11.5	91

162	Gene Expression Correlated with Severe Asthma Characteristics Reveals Heterogeneous Mechanisms of Severe Disease. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 1449-1463	10.2	87
161	Development and validation of the Composite Asthma Severity Index--an outcome measure for use in children and adolescents. *Journal of Allergy and Clinical Immunology*, **2012**, 129, 694-701	11.5	87
160	Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β-agonist treatment in a multiethnic asthma population: a genetic study. *Lancet Respiratory Medicine,the*, **2014**, 2, 204-13	35.1	85
159	Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF-alpha. *Journal of Immunology*, **2007**, 179, 4840-8	5.3	85
158	Asthma phenotypes in inner-city children. *Journal of Allergy and Clinical Immunology*, **2016**, 138, 1016-1029	12.5	82
157	Histamine inhibition of neutrophil lysosomal enzyme release: an H2 histamine receptor response. *Science*, **1976**, 194, 737-8	33.3	78
156	Biological treatments for severe asthma: A major advance in asthma care. *Allergology International*, **2019**, 68, 158-166	4.4	77
155	Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. *Advances in Therapy*, **2018**, 35, 737-748	4.1	77
154	Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. *Journal of Allergy and Clinical Immunology*, **2013**, 131, 339-45	11.5	76
153	Host immune responses to rhinovirus: mechanisms in asthma. *Journal of Allergy and Clinical Immunology*, **2008**, 122, 671-682	11.5	75
152	A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. *Journal of Allergy and Clinical Immunology*, **2010**, 125, 803-13	11.5	71
151	Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. *Journal of Asthma*, **1997**, 34, 321-8	1.9	70
150	Similar colds in subjects with allergic asthma and nonatopic subjects after inoculation with rhinovirus-16. *Journal of Allergy and Clinical Immunology*, **2009**, 124, 245-52, 252.e1-3	11.5	69
149	Addressing issues of asthma in inner-city children. *Journal of Allergy and Clinical Immunology*, **2007**, 119, 43-9	11.5	69
148	Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. *Journal of Allergy and Clinical Immunology*, **2003**, 111, 57-65	11.5	69
147	Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents. *Journal of Allergy and Clinical Immunology*, **2016**, 138, 1030-1041	11.5	69
146	Biomarkers in asthmatic patients: Has their time come to direct treatment?. *Journal of Allergy and Clinical Immunology*, **2016**, 137, 1317-24	11.5	68
145	Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. *Chest*, **2013**, 144, 1222-1229	5.3	67

144	Childhood- versus adult-onset asthma. *American Journal of Respiratory and Critical Care Medicine*, **1995**, 151, 1635-9	10.2	67
143	The Urban Environment and Childhood Asthma (URECA) birth cohort study: design, methods, and study population. *BMC Pulmonary Medicine*, **2009**, 9, 17	3.5	65
142	The effect of azelastine on neutrophil and eosinophil generation of superoxide. *Journal of Allergy and Clinical Immunology*, **1989**, 83, 400-5	11.5	65
141	The poorly explored impact of uncontrolled asthma. *Chest*, **2013**, 143, 511-523	5.3	63
140	Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. *Respiratory Medicine*, **2012**, 106, 642-50	4.6	63
139	The relationship of rhinovirus-associated asthma hospitalizations with inhaled corticosteroids and smoking. *Journal of Infectious Diseases*, **2006**, 193, 1536-43	7	62
138	Future research directions in asthma: an NHLBI Working Group report. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 170, 683-90	10.2	61
137	Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. *Thorax*, **2014**, 69, 312-9	7.3	60
136	Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. *Thorax*, **2012**, 67, 35-41	7.3	60
135	Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the 2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial. *Thorax*, **2013**, 68, 513-20	7.3	59
134	Are there neurophenotypes for asthma? Functional brain imaging of the interaction between emotion and inflammation in asthma. *PLoS ONE*, **2012**, 7, e40921	3.7	59
133	Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. *European Respiratory Journal*, **2014**, 43, 773-82	13.6	58
132	Characteristics of perimenstrual asthma and its relation to asthma severity and control: data from the Severe Asthma Research Program. *Chest*, **2013**, 143, 984-992	5.3	58
131	24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. *European Respiratory Journal*, **2012**, 40, 570-9	13.6	57
130	Determinants of exhaled breath condensate pH in a large population with asthma. *Chest*, **2011**, 139, 328-336	5.3	56
129	Biologics in asthma--the next step toward personalized treatment. *Journal of Allergy and Clinical Immunology: in Practice*, **2015**, 3, 152-60; quiz 161	5.4	55
128	Pathways through which asthma risk factors contribute to asthma severity in inner-city children. *Journal of Allergy and Clinical Immunology*, **2016**, 138, 1042-1050	11.5	54
127	Transcriptome networks identify mechanisms of viral and nonviral asthma exacerbations in children. *Nature Immunology*, **2019**, 20, 637-651	19.1	52

126	House dust mite sublingual immunotherapy: results of a US trial. *Journal of Allergy and Clinical Immunology*, **2011**, 127, 974-81.e1-7	11.5	52
125	Combined Analysis of Asthma Safety Trials of Long-Acting Agonists. *New England Journal of Medicine*, **2018**, 378, 2497-2505	59.2	50
124	Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. *Journal of Allergy and Clinical Immunology: in Practice*, **2013**, 1, 163-71	5.4	49
123	Up-regulation and activation of eosinophil integrins in blood and airway after segmental lung antigen challenge. *Journal of Immunology*, **2008**, 180, 7622-35	5.3	49
122	Predicting intermediate phenotypes in asthma using bronchoalveolar lavage-derived cytokines. *Clinical and Translational Science*, **2010**, 3, 147-57	4.9	47
121	Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies. *Journal of Allergy and Clinical Immunology: in Practice*, **2017**, 5, S1-S14	5.4	45
120	Development of cockroach immunotherapy by the Inner-City Asthma Consortium. *Journal of Allergy and Clinical Immunology*, **2014**, 133, 846-52.e6	11.5	42
119	Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. *Annals of Allergy, Asthma and Immunology*, **2012**, 109, 353-358.e4	3.2	41
118	Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. *Current Medical Research and Opinion*, **2007**, 23, 2379-86	2.5	41
117	Asthma diagnosis and treatment: filling in the information gaps. *Journal of Allergy and Clinical Immunology*, **2011**, 128, 740-50	11.5	39
116	Mind-body interactions in the regulation of airway inflammation in asthma: A PET study of acute and chronic stress. *Brain, Behavior, and Immunity*, **2016**, 58, 18-30	16.6	39
115	Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. *Journal of Allergy and Clinical Immunology*, **2008**, 121, 1407-14, 1414.e1-6	11.5	38
114	Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. *Respiratory Research*, **2011**, 12, 160	7.3	36
113	Clinical Implications of Having Reduced Mid Forced Expiratory Flow Rates (FEF25-75), Independently of FEV1, in Adult Patients with Asthma. *PLoS ONE*, **2015**, 10, e0145476	3.7	35
112	Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses. *Chest*, **2012**, 141, 1303-1314	5.3	34
111	Longitudinal changes in airway remodeling and air trapping in severe asthma. *Academic Radiology*, **2014**, 21, 986-93	4.3	33
110	Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. *Journal of Allergy and Clinical Immunology: in Practice*, **2014**, 2, 553-61	5.4	32
109	The National Institutes of Allergy and Infectious Diseases networks on asthma in inner-city children: an approach to improved care. *Journal of Allergy and Clinical Immunology*, **2010**, 125, 529-37; quiz 538-9	11.5	32

108	Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. *Journal of Family Practice*, **2001**, 50, 595-602	0.2	32
107	Efficacy and safety of fluticasone furoate 100 g once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial. *Respiratory Medicine*, **2014**, 108, 41-9	4.6	31
106	Severe asthma: an expanding and mounting clinical challenge. *Journal of Allergy and Clinical Immunology: in Practice*, **2013**, 1, 110-21; quiz 122	5.4	31
105	An expert consensus framework for asthma remission as a treatment goal. *Journal of Allergy and Clinical Immunology*, **2020**, 145, 757-765	11.5	31
104	Roflumilast for asthma: Efficacy findings in placebo-controlled studies. *Pulmonary Pharmacology and Therapeutics*, **2015**, 35 Suppl, S20-7	3.5	30
103	Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. *Annals of Allergy, Asthma and Immunology*, **2006**, 96, 60-8	3.2	30
102	Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma. *European Respiratory Journal*, **2019**, 53,	13.6	30
101	Rhinitis in children and adolescents with asthma: Ubiquitous, difficult to control, and associated with asthma outcomes. *Journal of Allergy and Clinical Immunology*, **2019**, 143, 1003-1011.e10	11.5	30
100	Can we predict fall asthma exacerbations? Validation of the seasonal asthma exacerbation index. *Journal of Allergy and Clinical Immunology*, **2017**, 140, 1130-1137.e5	11.5	28
99	Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?. *European Respiratory Review*, **2016**, 25, 54-64	9.8	28
98	Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine. *Journal of Allergy and Clinical Immunology*, **2011**, 127, 130-7, 137.e1-3	11.5	28
97	New directions and dimensions in the treatment of allergic rhinitis. *Journal of Allergy and Clinical Immunology*, **1988**, 82, 890-900	11.5	27
96	The inhaled Steroid Treatment as Regular Therapy in early asthma (START) study: rationale and design. *Contemporary Clinical Trials*, **2001**, 22, 405-19		26
95	Safety and tolerability of once-daily tiotropium Respimat( ) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis. *Respiratory Medicine*, **2016**, 118, 102-111	4.6	26
94	Characterization of factors associated with systemic corticosteroid use in severe asthma: data from the Severe Asthma Research Program. *Journal of Allergy and Clinical Immunology*, **2014**, 133, 915-8	11.5	25
93	How cytokines co-occur across asthma patients: from bipartite network analysis to a molecular-based classification. *Journal of Biomedical Informatics*, **2011**, 44 Suppl 1, S24-S30	10.2	25
92	Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: role of predictors in the setting of high adherence. *Journal of Allergy and Clinical Immunology*, **2009**, 124, 213-21, 221.e1	11.5	24
91	Discriminating sputum-eosinophilic asthma: Accuracy of cutoffs in blood eosinophil measurements versus a composite index, ELEN. *Journal of Allergy and Clinical Immunology*, **2015**, 136, 812-814.e2	11.5	23

90	Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. *Annals of Allergy, Asthma and Immunology*, **2017**, 119, 524-532.e2	3.2	22
89	Investigation of the relationship between IL-6 and type 2 biomarkers in patients with severe asthma. *Journal of Allergy and Clinical Immunology*, **2020**, 145, 430-433	11.5	22
88	Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma. *Journal of Allergy and Clinical Immunology*, **2018**, 142, 1856-1866	11.5	21
87	New and Anticipated Therapies for Severe Asthma. *Journal of Allergy and Clinical Immunology: in Practice*, **2017**, 5, S15-S24	5.4	21
86	In vitro incubation with influenza virus primes human polymorphonuclear leukocyte generation of superoxide. *American Journal of Respiratory Cell and Molecular Biology*, **1991**, 4, 347-54	5.7	21
85	Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma. *Annals of Allergy, Asthma and Immunology*, **2020**, 124, 190-196	3.2	21
84	BAL Cell Gene Expression in Severe Asthma Reveals Mechanisms of Severe Disease and Influences of Medications. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 837-856	10.2	20
83	Expression quantitative trait locus fine mapping of the 17q12-21 asthma locus in African American children: a genetic association and gene expression study. *Lancet Respiratory Medicine,the*, **2020**, 8, 482-492	35.1	20
82	Obstruction phenotype as a predictor of asthma severity and instability in children. *Journal of Allergy and Clinical Immunology*, **2018**, 142, 1090-1099.e4	11.5	20
81	Phenotype of asthmatics with increased airway S-nitrosoglutathione reductase activity. *European Respiratory Journal*, **2015**, 45, 87-97	13.6	20
80	Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. *Journal of Allergy and Clinical Immunology: in Practice*, **2020**, 8, 527-539.e9	5.4	20
79	Designing clinical trials to address the needs of childhood and adult asthma: the National Heart, Lung, and Blood Institute's AsthmaNet. *Journal of Allergy and Clinical Immunology*, **2014**, 133, 34-8.e1	11.5	19
78	Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. *European Respiratory Journal*, **2021**, 58,	13.6	19
77	A role for neutrophils in asthma exacerbations. *Nature Medicine*, **2017**, 23, 658-659	50.5	18
76	The brain and asthma: what are the linkages?. *Chemical Immunology and Allergy*, **2012**, 98, 14-31		18
75	Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. *Annals of Allergy, Asthma and Immunology*, **2020**, 125, 565-576.e1	3.2	17
74	Efficacy and safety of fluticasone furoate 100 g and 200 g once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. *BMC Pulmonary Medicine*, **2014**, 14, 113	3.5	17
73	Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. *Respiratory Research*, **2014**, 15, 88	7.3	17

72	Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study. *Clinical Therapeutics*, **2004**, 26, 1587-98	3.5	17
71	Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. *Journal of Asthma*, **2021**, 58, 514-522	1.9	17
70	Biological treatments for severe asthma: where do we stand?. *Current Opinion in Allergy and Clinical Immunology*, **2018**, 18, 509-518	3.3	17
69	Asthma: diagnosis and management. *Medical Clinics of North America*, **2006**, 90, 39-60	7	16
68	Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. *Lancet Respiratory Medicine,the*, **2021**, 9, 1165-1173	35.1	16
67	genotype identifies glucocorticoid responsiveness in severe asthma. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 2187-2193	11.5	15
66	Expression of asthma susceptibility genes in bronchial epithelial cells and bronchial alveolar lavage in the Severe Asthma Research Program (SARP) cohort. *Journal of Asthma*, **2016**, 53, 775-82	1.9	15
65	Airway factor XIII associates with type 2 inflammation and airway obstruction in asthmatic patients. *Journal of Allergy and Clinical Immunology*, **2016**, 137, 767-73.e6	11.5	15
64	Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. *Journal of Negative Results in BioMedicine*, **2014**, 13, 9		15
63	What is the best pulmonary diagnostic approach for wheezing patients with normal spirometry?. *Respiratory Care*, **2012**, 57, 39-46; discussion 47-9	2.1	15
62	Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma. *Journal of Asthma and Allergy*, **2019**, 12, 401-413	3.1	15
61	Tiotropium add-on to inhaled corticosteroids versus addition of long-acting □agonists for adults with asthma. *Respiratory Medicine*, **2018**, 143, 82-90	4.6	15
60	The role of respiratory viruses in asthma. *Novartis Foundation Symposium*, **1997**, 206, 208-13; discussion 213-9		15
59	Reducing Exacerbations in the Inner City: Lessons from the Inner-City Asthma Consortium (ICAC). *Journal of Allergy and Clinical Immunology: in Practice*, **2016**, 4, 22-6	5.4	14
58	Treatment regimen and side effects of treatment measures. *American Journal of Respiratory and Critical Care Medicine*, **1994**, 149, S44-50; discussion S51-3	10.2	14
57	Serum IL-6: A□biomarker in childhood asthma?. *Journal of Allergy and Clinical Immunology*, **2020**, 145, 1701-1704.e3	11.5	13
56	Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. *BMC Pulmonary Medicine*, **2016**, 16, 65	3.5	13
55	IgE-mediated asthma: New revelations and future insights. *Respiratory Medicine*, **2016**, 112, 128-9	4.6	13

54	Effect of Bordetella pertussis vaccination in mice and the isolated tracheal response to isoprenaline. *Allergy: European Journal of Allergy and Clinical Immunology*, **1980**, 35, 291-6	9.3	13
53	Is the eosinophil a "Humpty Dumpty" cell in asthma?. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 167, 102-3	10.2	12
52	Roflumilast for asthma: Safety findings from a pooled analysis of ten clinical studies. *Pulmonary Pharmacology and Therapeutics*, **2015**, 35 Suppl, S28-34	3.5	11
51	Biologic Therapy and Asthma. *Seminars in Respiratory and Critical Care Medicine*, **2018**, 39, 100-114	3.9	11
50	The role of allergy in disease. *Immunological Reviews*, **2011**, 242, 5-9	11.3	11
49	Biologic therapies for asthma. *Current Opinion in Pulmonary Medicine*, **2010**, 16, 19-24	3	10
48	Corticosteroids in the Treatment of Asthma. *BioDrugs*, **1995**, 4, 16-48		10
47	Benefits of Airway Androgen Receptor Expression in Human Asthma. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, 285-293	10.2	10
46	Controversies and opportunities in severe asthma. *Current Opinion in Pulmonary Medicine*, **2018**, 24, 83-93	3	9
45	Anti-immunoglobulin E for the treatment of allergic disease. *Current Opinion in Allergy and Clinical Immunology*, **2001**, 1, 105-108	3.3	9
44	What is the contribution of IgE to nasal polyposis?. *Journal of Allergy and Clinical Immunology*, **2021**, 147, 1997-2008	11.5	9
43	A Deep Dive into Asthma Transcriptomics. Lessons from U-BIOPRED. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 1279-1280	10.2	8
42	Preliminary safety and efficacy of daclizumab in the treatment of patients with moderate to severe chronic persistent asthma*1. *Journal of Allergy and Clinical Immunology*, **2004**, 113, S286-S287	11.5	8
41	A computerized decision support tool to implement asthma guidelines for children and adolescents. *Journal of Allergy and Clinical Immunology*, **2019**, 143, 1760-1768	11.5	8
40	Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity. *Journal of Allergy and Clinical Immunology: in Practice*, **2020**, 8, 2673-2680.e3	5.4	7
39	Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. *Respiratory Research*, **2016**, 17, 157	7.3	7
38	Dust Mite-Induced Perennial Allergic Rhinitis in Pediatric Patients and Sublingual Immunotherapy. *Journal of Allergy and Clinical Immunology: in Practice*, **2017**, 5, 46-51	5.4	7
37	Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment. *Journal of Allergy and Clinical Immunology*, **2021**, 148, 266-271.e2	11.5	7

36	Global Initiative for Asthma 2016-derived asthma control with fluticasone propionate and salmeterol: A Gaining Optimal Asthma Control (GOAL) study reanalysis. *Annals of Allergy, Asthma and Immunology*, **2019**, 123, 57-63.e2	3.2	6
35	Anaphylaxis Conundrum: A Trojan Horse Phenomenon. *Journal of Allergy and Clinical Immunology: in Practice*, **2017**, 5, 325-329	5.4	6
34	The Relationship of Asthma Biologics to Remission for Asthma. *Journal of Allergy and Clinical Immunology: in Practice*, **2021**, 9, 1090-1098	5.4	6
33	Aeroallergen Sensitization, Serum IgE, and Eosinophilia as Predictors of Response to Omalizumab Therapy During the Fall Season Among Children with Persistent Asthma. *Journal of Allergy and Clinical Immunology: in Practice*, **2020**, 8, 3021-3028.e2	5.4	5
32	Executive Summary: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. *Annals of the American Thoracic Society*, **2014**, 11 Suppl 3, S123-4	4.7	5
31	Biologicals for asthma in patients with asthma-COPD overlap. *Lancet Respiratory Medicine,the*, **2017** , 5, 175-177	35.1	4
30	Is It Asthma or Is It COPD: The Overlap Syndrome. *Journal of Allergy and Clinical Immunology: in Practice*, **2015**, 3, 641-2; quiz 643	5.4	4
29	Expression of corticosteroid-regulated genes by PBMCs in children with asthma. *Journal of Allergy and Clinical Immunology*, **2019**, 143, 940-947.e6	11.5	4
28	Effect of nedocromil sodium on the beta-adrenergic response of human polymorphonuclear leucocytes. *Drugs*, **1989**, 37 Suppl 1, 26-31; discussion 69-77	12.1	4
27	How to compare the efficacy of biologic agents in asthma. *Annals of Allergy, Asthma and Immunology*, **2020**, 125, 137-149	3.2	3
26	Determinants of risk factors for asthma. *Canadian Respiratory Journal*, **1999**, 6, 97-101	2.1	3
25	Uncontrolled asthma across GINA treatment steps 2 - 5 in a large US patient cohort. *Journal of Asthma*, **2021**, 1-13	1.9	3
24	Anti-immunoglobulin E for the treatment of allergic disease. *Current Opinion in Allergy and Clinical Immunology*, **2001**, 1, 105-8	3.3	3
23	Cysteinyl Leukotrienes in Allergic Inflammation. *Chest*, **2005**, 127, 1312-1326	5.3	2
22	Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations. *Journal of Allergy and Clinical Immunology: in Practice*, **2021**, 9, 1201-1211	5.4	2
21	Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma. *European Respiratory Journal*, **2021**, 58,	13.6	2
20	Neuroimaging and biomarker evidence of neurodegeneration in asthma. *Journal of Allergy and Clinical Immunology*, **2021**,	11.5	2
19	An Integrated Analysis of Fluticasone Furoate/Vilanterol (FF/VI) Versus FF Safety Data Across Phase II and III Asthma Studies. *Pulmonary Therapy*, **2016**, 2, 91-114	3	1

18	A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Comparing the Efficacy and Tolerability of Levocabastine-Oxymetazoline Nasal Spray with Levocabastine and Oxymetazoline Alone in the Symptomatic Treatment of Seasonal Allergic Rhinitis. *American Journal of Rhinology & Allergy*, **1996**, 10, 105-112		1
17	Inducible expression quantitative trait locus analysis of the MUC5AC gene in asthma in urban populations of children. *Journal of Allergy and Clinical Immunology*, **2021**, 148, 1505-1514	11.5	1
16	Cockroach-induced IL9, IL13, and IL31 expression and the development of allergic asthma in urban children. *Journal of Allergy and Clinical Immunology*, **2021**, 147, 1974-1977.e3	11.5	1
15	Holy Grail: the journey towards disease modification in asthma.. *European Respiratory Review*, **2022**, 31,	9.8	1
14	Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study. *BMC Pulmonary Medicine*, **2017**, 17, 75	3.5	0
13	In lasting tribute: Charles E. Reed, March 13, 1922, to July 24, 2020. *Journal of Allergy and Clinical Immunology*, **2020**, 146, 984-986	11.5	0
12	Development of nasal allergen challenge with cockroach in children with asthma. *Pediatric Allergy and Immunology*, **2021**, 32, 971-979	4.2	0
11	Prevention and Treatment of Asthma Exacerbations in Adults. *Journal of Allergy and Clinical Immunology: in Practice*, **2021**, 9, 2578-2586	5.4	0
10	Reply. *Journal of Allergy and Clinical Immunology*, **2017**, 139, 1408-1409	11.5	
9	Reply: To PMID 23591271. *Journal of Allergy and Clinical Immunology*, **2014**, 133, 1231	11.5	
8	Authors' reply to 'Safety and tolerability of fluticasone furoate/vilanterol'. *Thorax*, **2013**, 68, 1165-6	7.3	
7	Combination low-dose metaproterenol-theophylline therapy in asthma. *Journal of Asthma*, **1983**, 20, 85-91	1.9	
6	The Asthma Guidelines: What Do the Experts Teach Us? **2008**, 165-176		
5	Novel Biologicals Alone and in Combination in Asthma and Allergy203-231		
4	Management of Asthma in Adolescents and Adults **2014**, 902-922		
3	Reply. *Journal of Allergy and Clinical Immunology*, **2020**, 146, 1214-1215	11.5	
2	Reply. *Journal of Allergy and Clinical Immunology*, **2019**, 143, 1267-1268	11.5	
1	Safety Trials of Long-Acting Agonists. *New England Journal of Medicine*, **2018**, 379, 1482	59.2	